Chagee (NasdaqGS:CHA) Q4 2025 Earnings call March 31, 2026 08:00 AM ET Company ParticipantsAaron Huang - CFOAlicia Guo - Investor Relations DirectorDengfeng Yin - Director and Chief Operating OfficeJunjie Zhang - Chairman and CEOConference Call ParticipantsJessie Xu - AnalystLillian Lou - AnalystSijie Lin - AnalystXiaopo Wei - AnalystOperatorGood morning and good evening, ladies and gentlemen. Thank you for standing by and welcome to Chagee's fourth quarter 2025 earnings conference call. At this time, all p ...

Core Insights - The company achieved record annual revenue of $1.3 billion and adjusted EBITDA of $210 million, driven by the resilience of the distributed gaming model and contributions from new acquisitions [1] Financial Performance - Annual revenue reached $1.3 billion with adjusted EBITDA of $210 million, indicating strong financial performance [1] Operational Strategy - The company optimized its Illinois and Montana operations by focusing on higher-yielding machine placements and route density, successfully expanding margins despite flat location counts [1] - Demonstrated rapid deployment capabilities in Nevada by launching 55 Rebel Convenience Store locations in just six days, showcasing the scalability of the national operating infrastructure [1] Market Positioning - Positioned as a 'buyer of choice' in Louisiana, leveraging the Toucan Gaming platform to execute a bolt-on acquisition strategy within a healthy consolidation pipeline [1] - Transitioned the business model from a logistics-heavy operation toward a differentiated entertainment and hospitality business focused on proprietary content and niche market positioning [1] Capital Management - Maintained a disciplined capital allocation framework that balanced $300 million in liquidity against organic growth, strategic M&A, and the repurchase of 3.8 million shares [1] Leadership Changes - Announced a leadership succession plan where CEO Andy Rubenstein moves to Chairman to focus on high-level relationships, while Mark Phelan prepares to assume day-to-day leadership [1]

Core Insights - Supernus Pharmaceuticals achieved record revenues of $719 million in 2025, driven by a 40% revenue increase from four key products: Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO, which now account for 76% of total revenues [4] - The company successfully integrated the acquisition of Sage Therapeutics, adding ZURZUVAE to its portfolio and establishing a presence in the women's health and postpartum depression markets [4] - Projected total revenues for 2026 are estimated to be between $840 million and $870 million, with ONAPGO expected to contribute $45 million to $70 million as supply stabilizes [4] Strategic Performance and Operational Context - The company managed ONAPGO supply constraints by prioritizing existing patient maintenance and preparing to resume new patient initiations in early 2026 [4] - Qelbree's fourth-quarter net sales lagged behind prescription growth due to an unexpected $4 million PBM bill for the full year of 2025 [4] - The company maintains a disciplined R&D approach, retaining high-potential Sage assets for internal development while seeking external partnerships for early-stage pipeline candidates [4] 2026 Outlook and Strategic Priorities - The strategic focus for 2026 includes clearing the ONAPGO patient backlog and transitioning to a second manufacturing supplier by 2027 to ensure long-term capacity [4] - The M&A strategy is focused on revenue-generating assets or late-stage pipeline candidates that could launch between 2027 and 2031 [4] - Clinical timelines for SPN-820 (depression) and SPN-817 (epilepsy) target top-line data readouts in 2027, with SPN-820 expected to recruit faster due to the indication type [4] Financial Performance - The company recorded $73 million in acquisition-related costs and $50 million in incremental operating costs associated with the Sage Therapeutics transaction in 2025 [4] - A GAAP operating loss of $62.3 million was reported for 2025, primarily due to one-time acquisition expenses and higher intangible asset amortization for new products [4] Market Opportunities - A 700-patient queue for ONAPGO awaiting benefit verification represents a significant near-term revenue conversion opportunity as supply resumes [6] - High demand for ONAPGO exists, but the conversion of 1,800 enrollment forms to active patients is subject to typical specialty pharmacy attrition and reimbursement hurdles [6]

Core Viewpoint - Sirius XM is perceived as a value stock with a sticky subscription model, strong free cash flow, and shareholder returns, yet its stock has declined 34% over the past year due to negative market sentiment [1] Group 1: Strengths - Sirius XM's revenue is largely predictable, with 76% of its projected $8.7 billion revenue in 2024 coming from subscriptions, leading to a free cash flow of $1 billion [3] - The company has maintained a low churn rate of under 2% over the past five years, indicating strong customer retention among car owners [4] - Over the past seven years, Sirius XM has returned nearly $7.5 billion to shareholders through buybacks and has consistently paid dividends, reflecting a shareholder-friendly capital allocation strategy [5][6] Group 2: Weaknesses - Sirius XM's growth has been negative, with a price-to-free-cash-flow ratio of 7.3 times, down approximately 50% over the last five years [7] - Revenue has declined from $9 billion to $8.7 billion over the last two years, and paid subscribers have decreased from a peak of 34.9 million in 2019 to 33.2 million in 2024 [8] - The company struggles to compete in the booming audio space, with its streaming and podcast revenue remaining flat at around $2 billion over the last four years, while monthly active users have declined [9][10] Group 3: Future Outlook - The stock could be considered a bargain if Sirius XM can stabilize its subscriber base and successfully monetize its digital platforms [11][12] - The company is exploring new monetization strategies, including a low-priced ad-supported subscription service and efforts to revitalize its podcast business [12] - However, if the decline in revenue and subscribers is structural, the current low valuation may reflect a deeper issue rather than a buying opportunity [13][14]

Financial Data and Key Metrics Changes - The company reported revenues of $63.9 million for Q2 2025, exceeding guidance of $51 million to $61 million, but reflecting an 11.6% sequential decline and a 42% year-over-year decline [22][23] - Gross margin improved to 72.3%, a 300 basis point increase year-over-year, exceeding the long-term target of 65% to 70% [5][23] - Adjusted EBITDA was $4.6 million, marking the seventh consecutive quarter of positive adjusted EBITDA [22][28] - The company achieved a cumulative $39.5 million in adjusted EBITDA over the past seven quarters [6] Business Line Data and Key Metrics Changes - Digital revenue decreased by 7.5% sequentially to $39.7 million and declined 32.5% year-over-year, with digital subscribers down 7.8% sequentially to 940,000 [25][26] - Nutrition revenue fell 15.6% sequentially to $24.2 million and decreased 51.8% year-over-year, with nutrition subscriptions down 12.5% sequentially to 70,000 [25][26] - Digital gross margin was 87.7%, an increase from the prior quarter and year, while nutrition gross margin was 51.4%, reflecting a decline due to promotional offerings [26] Market Data and Key Metrics Changes - The company is transitioning from a multilevel marketing (MLM) model to an omnichannel model, which has impacted revenue in the near term [22][23] - The anticipated revenue split moving forward is approximately 63% digital and 37% nutrition [31] Company Strategy and Development Direction - The company plans to launch Shakeology in retail in early 2026, marking its first entry into brick-and-mortar sales [7][45] - A new P90X nutritional line and Insanity branded supplements are also set for retail launch, creating cross-marketing opportunities [8][20] - The strategic focus is on building a diverse product portfolio and leveraging brand equity to drive growth [9][10] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that while 2025 may see temporary revenue declines, it is building towards significant growth opportunities [7][10] - The company is focused on disciplined execution and believes it is well-positioned for long-term success [11][21] - Management expressed confidence in achieving positive free cash flow for the full year of 2025 for the first time since 2020 [6][30] Other Important Information - The company reduced its revenue breakeven point from approximately $900 million in 2022 to about $200 million in 2025 [6] - Operating expenses decreased by 9.1% sequentially and 41.5% year-over-year, reflecting the shift away from the MLM model [27] Q&A Session Summary Question: What drove the higher gross margin in the quarter? - The higher gross margin was driven by reduced production spend and fewer fixed costs allocated to production [34] Question: What is the expected level of selling and marketing expenses going forward? - Selling and marketing expenses have decreased significantly since exiting the MLM model, with a goal to reduce them to the mid-thirties percentage of revenue [36][37] Question: Are there plans to roll out new supplements to complement the nutrition business? - Yes, the company plans to launch new nutritional products in retail starting in 2026, including Shakeology and P90X supplements [45][46] Question: What is the status of the nutrition retail launch? - The company is preparing sales presentations for major retailers and expects to begin retail sales in early 2026 [55] Question: Will the Shakeology product have new packaging for retail? - Yes, Shakeology will have a complete packaging refresh designed for retail, highlighting its major brand status [58][59]